Emerging Med - Secondary
 SEARCH BY PHONE
1.877.601.8601
8:30 AM - 6:00 PM EST (M-F)
Find trials
that match your profile.
 




 




 
   
 
Our Mission
Our Goal
Our Privacy Policy
Our Services
Our History
Our Management
Our Medical Advisory Board
Our Patient/Advocate Advisory Board 		  Content
How We Get Paid
Sponsorship
Strategic Alliances
Become an Advisor
Join Our Team
Letter from the CEO

 
 

Our Mission   Top
EmergingMed's mission is to leverage the power of the Internet to increase treatment options for people with serious illnesses and to speed up drug development through increased enrollment in clinical trials.

 
 
 

Our Goal   Top
EmergingMed's goal is to become the central repository of clinical research information in the United States and to provide a fast, simple way for people with serious illnesses to search for and gain access to clinical trial options.

 
 
 

Our Privacy Policy   Top
Our commitment to privacy and security is uncompromising and guides every decision we make. All information submitted to EmergingMed is password protected, confidential and secure. We will never sell or share your personal information. See our  Privacy Policy for more information.

 
 
 

Our Services   Top
EmergingMed offers a free online tool that helps cancer patients find appropriate clinical trials in a matter of minutes.

  1. Fill out a patient profile and click "match to trials"

    EmergingMed has created unparalleled matching technology that allows people with serious illnesses and their caregivers to compare a short personal profile to the enrollment criteria of thousands of clinical trials in a matter of minutes. The matching is performed in a secure environment that protects the confidentiality of both the person filling out the patient profile and the organization conducting the research.

    The list of clinical trials that match a patient profile is presented in an unbiased format – privately sponsored and public trials are given equal weight – so that the user may decide on the best option for their own situation. EmergingMed includes only those trials that have been approved by the Institutional Review Board (IRB) of the hospital or doctor's office where the trial is taking place. See About Clinical Trials for more details. In some instances, such as when a user enters the EmergingMed website from a cancer center subscriber website, the trials administered in that cancer center might appear before other trials.

  2. Review your trial matches

    We encourage you to print out the trials that you match to so that you may discuss them with your physician or another healthcare professional. You might also take a look at the "Therapies in Development" section of the EmergingMed website for short articles describing promising new cancer therapies with a link to the relevant medical journal abstract.

  3. Submit an application -- our staff will help you contact the clinical trial

    If you decide to submit an application to clinical trials that you have matched to in the EmergingMed database, you can elect to be contacted by phone or email by EmergingMed staff. An EmergingMed Member Services representative will first call you to verify your interest in the clinical trial(s). The Member Services representative will then contact the trial administrator and make arrangements for you to speak to the trial administrator. We strive to contact by phone the same day an application is submitted. If email contact is selected, the user will receive a response within 48 hours at their email address.

    EmergingMed will persist on behalf of the prospective study participant until a connection is made with the trial administrator. After that connection is made, EmergingMed staff may follow up with the study participant and the trial coordinator to determine whether the patient is enrolled in the study.

 
 
 

Our History   Top
After months of interviews with patients, advocates, caregivers and researchers, EmergingMed was founded in January 2000 to offer patients and their families a fast and easy way to find and understand available treatment options. The website officially launched in December 2000 and has been steadily increasing the number of patients matched to clinical trials since then.

 
 
 

Our Management   Top

 
 
Courtney Hudson   Courtney Hudson, CEO and Founder
Courtney co-founded EmergingMed in January 2000 after spending three years as a health services analyst and institutional sales representative with CIBC Oppenheimer. Prior to joining Oppenheimer, Courtney was co-founder and Vice President of Business Development & Information Systems with a multi-state Medicaid-focused HMO start-up. In addition to two other HMO start-ups, Courtney has worked for a variety of academic medical centers and county public health agencies/clinics where she cultivated expertise in the design and operation of efficient health care delivery systems for vulnerable populations. Courtney holds an M.B.A. (supplemented with extensive training through the School of Public Health) from the University of Washington as well as a B.S. in Biology from Yale University. Read the Letter from the CEO to learn how Courtney became committed to improving patients' access to clinical trials.
 
Tal Barnea, Chief Technology Officer
Tal brings 20 years of software development and information technology management experience to EmergingMed. As Senior Director of Application Development at Skila, a global healthcare intelligence company, Tal delivered many of the company's new product releases and led the change of product architecture from a desktop application to a web-based platform. As the company grew from 15 to over 100 employees, he designed and managed development of numerous applications integrating multi-sourced healthcare information in to a single delivery platform.   Most recently Tal managed both system and development teams for Pearson Education's global family of language instruction products. He was instrumental in the launch of Pearson's 24x7 application service provider (ASP) based hosted platform as well the associated CD-ROM based products.   Previously, Tal developed software for NYNEX's Expert Systems Group and served on the Computing Resources Group steering committee. At Philips Labs, he assisted the company's transition from proprietary to open technologies and was involved in the development of an interactive video and data services application.   Tal holds a M.Sc. degree in computer science from Columbia University in New York.
 
Anne Clothier, Vice President of Business Development
Anne brings 15 years of pharmaceutical industry experience to EmergingMed. Most recently, she worked as the Group Product Director of Strategic Marketing with the McNeil Specialty Pharmaceuticals division of Johnson & Johnson. In this role, she was responsible for the business strategy and commercial development of all pipeline products for McNeil. Prior to Johnson & Johnson, Anne worked at Merck & Co., Inc. for over 11 years in a number of different marketing assignments. She brings significant experience in marketing management and strategy development. In addition, she brings diverse experience in developing and implementing new business opportunities. Anne holds a MBA degree in Finance from The Wharton School of the University of Pennsylvania and a BA in History from Yale University.
 
Garry Carneal, Executive Director of Strategic Alliances
Garry brings 20 years of business development, accreditation, and legal experience to EmergingMed. From 1996 to 2005, he served as President & CEO of URAC, a nonprofit accreditation agency. During his tenure, Garry expanded and diversified URAC into one of the premier quality benchmarking organizations in the United States. Recently, he also has served as President of a medical management organization providing case and disease management services to over 150,000 individuals. Previously, Garry headed up the state government affairs and legal departments at the American Association of Health Plans. He also served as the chief federal legislative counsel for the National Association of Insurance Commissioners. He has researched, written and published extensively on quality, medical management, information technology, and regulatory trends. He has an established track record in helping trade associations, certification agencies, and businesses expand their health care operations nationally. Mr. Carneal is a member of several non-profit boards, including the American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) and the Population Health Impact Institute (PHII). Garry received his JD from the University of Virginia, MA from Yale University, and BA from Washington & Lee University.
 
 
 
 

Our Medical Advisory Board   Top
EmergingMed works closely with distinguished physicians and clinical researchers who help to oversee our content, policies and procedures. The following is a list of our oncology advisory board members:

 
 
  Daniel D. Von Hoff, MD, (Chair) is currently Professor of Medicine, Molecular and Cellular Biology and Pathology, and Director of the Arizona Cancer Center at The University of Arizona in Tucson. He is also Co-Director of Clinical Research for US Oncology. Dr. Von Hoff is the immediate past President for the American Association for Cancer Research, a Fellow of the American College of Physicians and a member and past board member of the American Society for Clinical Oncology. He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; an Associate Editor of Clinical Cancer Research; and Co-Editor of ONE, ONcology Economics. He is on the editorial board of Anti-cancer Drugs and the International Journal of Oncology. He is also proud to have been a mentor and teacher for multiple medical oncology fellows, graduate students, and post-doctoral fellows.
 
  David S. Alberts, MD is Professor of Medicine, Pharmacology and Public Health, Director of Cancer Prevention and Control at the Arizona Cancer Center, and Associate Dean for Research in the College of Medicine. Dr. Alberts has been funded by the NCI yearly since 1975 for laboratory and clinical research related to the prevention and treatment of cancer, and has authored or co-authored over 400 peer-reviewed journal articles and 80 book chapters and books. Presently, he chairs the Gynecologic Cancer Committee in the Southwest Oncology Group and the Cancer Prevention and Control Committee of the Gynecologic Oncology Group.
 
  Robert Figlin, MD, FACP is Professor of Medicine and Urology, Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology, Departments of Medicine and Urology, Divisions of Hematology/Oncology and Urologic Oncology, UCLA School of Medicine, Jonsson Comprehensive Cancer Center.
 
  Henry S. Friedman, MD is the James B. Powell Jr. Professor of Oncology and co-director of the Clinical Neuro-Oncology Program of the Brain Tumor Center at Duke, Professor of Pediatrics and Associate Professor of Surgery and Medicine. Dr. Friedman is an internationally recognized neuro-oncologist with a career-long interest in the treatment of children and adults with brain and spinal cord tumors.

 
  Gabriel N. Hortobagyi, MD, FACP is Professor of Medicine, Chairman of the Department of Breast Medical Oncology and Nellie B. Connally Chair in Breast Cancer at the University of Texas M.D. Anderson Cancer Center. He is also the Director of the Breast Cancer Research Program at the same institution. Dr. Hortobagyi has over 350 full-length publications in peer-reviewed journals; more than 250 invited papers; and nearly 100 book chapters to his credit.

 
  William Gillies McKenna, MD, PhD is Chair, Department of Radiation Oncology, and Henry K. Pancoast Professor of Radiation Oncology at the University of Pennsylvania School of Medicine. Dr. McKenna won the American Cancer Society Faculty Research Award in 1991 and was nominated to the Board of Scientific Advisors of the National Cancer Institute in 1996. He is a Fellow of the Philadelphia College of Physicians and has held Associate Editor positions for several medical journals.
 
  Michael D. Prados, MD is Professor of Neurological Surgery and Chief of the Neuro-Oncology Program. He performs clinical trials and studies quality of life for patients undergoing brain tumor therapies. Dr. Prados is head of the National Cancer Institute's North American Brain Tumor Consortium, which sponsors trials of treatment regimens for brain tumors. He is also the principal investigator of the Pediatric Brain Tumor Consortium site at UCSF.
 
  Julie Vose, MD is Professor of Internal Medicine and Oncology/Hematology at the University of Nebraska Medical Center. Dr. Vose previously held the position of Vice Chairman, Department of Internal Medicine at the University of Nebraska Medical Center. Dr. Vose served on the FDA Advisory Board for Biological Response Modifiers from 1994 to 1997, and was Chairperson of the Board from 1996 to 1999. She is currently Chair of the lymphoma committee of the Autologous Bone Marrow Transplant Registry and President-elect of the Society.
 
 
 

Our Patient/Advocate Advisory Board   Top
EmergingMed also works closely with patients, families and patient advocates who have direct experience with cancer and cancer research. Many leaders in the advocacy community provide ongoing feedback on the barriers faced by patients and families trying to consider clinical trials as one of their treatment options.

 
 
 

Content   Top
EmergingMed features articles (click Standard Therapies or Therapies in Development) highlighting noteworthy research developments. Content is selected by our editorial staff and medical advisors, and presented with patient-friendly summaries that translate difficult medical information into lay terms. Overviews of treatment options are presented as feature articles that detail many of the standard therapies for a particular illness, often in the voices of patients, researchers, physicians and other caregivers. Users can find links to additional information and support in EmergingMed’s Resources section.

If you would like to submit an idea for article, call our editorial department at 877-601-8601. We pride ourselves in our journalistic integrity, so the decision to include content as well as the final edits are solely the responsibility of our editorial director. To learn more about our editorial policy click here.
 
 
 

How We Get Paid   Top
The matching and referral service is free to patients and physicians. EmergingMed receives monthly subscription fees from pharmaceutical and biotechnology companies to list and maintain their clinical trials in our database.

As a public service, EmergingMed lists, matches and refers patients to clinical trials sponsored by the government and other not-for-profit organizations free of charge.

 
 
 

Sponsorship   Top
EmergingMed is owned and operated by EmergingMed.com, Inc. at 160 Madison Avenue, 4th Floor, New York, NY 10016.

The company was created through investments from the founders, two venture capital firms (JT Venture Partners and CK Capital), and a number of private individuals. To ensure that our technology and customer services were unbiased and impartial, EmergingMed chose not to accept investments from pharmaceutical or biotechnology companies. In addition, EmergingMed does not accept advertising or sponsorship of content on its website, nor does it use "banner" or "pop-up" advertising on its website.

 
 
 

Strategic Alliances   Top
EmergingMed is actively seeking alliance partners that will help people with serious illnesses and their caregivers find and use our matching and referral service. We are also seeking partners that will help add to our growing database of cancer clinical trials. For information about how to become an alliance partner, click   here to email our Business Development department.

 
 
 

Become an Advisor   Top
Talking with patients, caregivers, and advocates to assess their needs and concerns about clinical trials and treatment information has been EmergingMed's practice since the Company's inception. Our belief is that by working closely with the very population our website has been built to serve, we will create a better and more responsible service. Indeed, feedback from patients, caregivers and advocates has helped us tailor our content and build our matching technology and it continues to be the basis for enhancements to our website.

If you would like to participate in EmergingMed focus groups, join our patient advisory team, contribute to our FAQ section or simply offer us feedback, please contact us via email at:  ContactUs@emergingmed.com.

 
 
 

Join Our Team   Top
EmergingMed is a great company for people who want to enjoy their job and have a positive impact on public health. Contact us to submit your resume and tell us more about how you can contribute to our team and our mission.

 
 
 

Letter from the CEO   Top
Late one Sunday evening In January 1999, my husband called me on his cell phone from a taxi. He was seriously ill and on his way to the hospital. The doctors were able to stabilize him temporarily, but they recommended additional surgery. My husband refused to undergo what would be a long, difficult operation that would require months of recovery. I was obviously upset - not only about my husband's condition, but also about his apparent unwillingness to accept treatment.

I was torn between the competing desires to respect his choices and for him to get treatment immediately. I began to search for treatment options, mainly through the Internet, but found the information presented too simplistic, too scientific, or too voluminous. By chance, a friend in California sent my husband an article about an alternative surgery that had only recently been developed. This surgery was being performed only a mile from our home in New York, yet we had never heard about it. My husband underwent the surgery, and today is doing fine.

We were lucky, but access to new treatment options, including clinical trials, should not be serendipitous. This is a time when pharmaceutical companies, biotech companies and the government have enlisted the support of nearly 50,000 doctors to conduct more than 10,000 clinical trials each year -- almost one-third are designed to test new drugs and therapies for cancer patients. Patients and families should have a way to find these new drugs and therapies without having to depend on luck.

After months of interviews with patients, advocates, caregivers, and researchers, Sarah Hutter, Glenn Rice and I founded EmergingMed.com in January 2000 to offer patients and their families a fast and easy way to find and understand available treatment options.

We have created the EmergingMed online matching and referral system to reliably connect patients directly to the doctors conducting clinical trials in a matter of minutes.

This personal journey, which started with a phone call from the back of a taxi, will hopefully benefit many others by providing more options for their own treatment and by accelerating the clinical research process that develops new drugs and therapies for all of us.

Sincerely,

Courtney Hudson
CEO and Founder, EmergingMed

 
© 2008 EmergingMed Home  |  Contact Us  |  How Matching Works  |  Privacy Policy  |  Terms & Conditions